Navigation Links
PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
Date:5/22/2009

Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the HHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, even with today's submission to the FDA, there can be no assurance that the Compan
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
2. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
5. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
6. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
7. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
8. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
9. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Rib-X Pharmaceuticals, Inc., a company ... novel drugs for the treatment of serious multi-drug-resistant ... collaborative research agreement with Massachusetts General Hospital (MGH). ... the collaboration, Dr. David Hooper of MGH will ... animal model to determine resistance development and to ...
(Date:12/15/2009)... Arlington Medical Resources (AMR) and Decision ... (MRSA) is the most concerning pathogen to surveyed ... treatment of skin and skin structure infections. A ... factors that influences European physician drug selection for ... factors that drive prescribing include an agent,s skin ...
(Date:12/15/2009)... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a ... announced today,that Weidong Yin, Chairman, President & ... to be one of 18 nominees for ... CCTV,s Economic Man-of-the-Year is the country,s ... to as the "Oscar Award of the,Chinese ...
Breaking Medicine Technology:Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3September is Prostate Cancer Awareness Month 54295 1September is Prostate Cancer Awareness Month 54295 2Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 1Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 2Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 3Cellular Dynamics International Appoints Leroy Hood M D Ph D and George Church Ph D to its Scientific Advisory Board 13518 1Cellular Dynamics International Appoints Leroy Hood M D Ph D and George Church Ph D to its Scientific Advisory Board 13518 2Cellular Dynamics International Appoints Leroy Hood M D Ph D and George Church Ph D to its Scientific Advisory Board 13518 3Cellular Dynamics International Appoints Leroy Hood M D Ph D and George Church Ph D to its Scientific Advisory Board 13518 4
... April 1 The Michael J. Fox Foundation ... up to $6.5 million in total funding available ... accelerate solutions to some of the most difficult ... for PD.The Critical Challenges funding opportunities focus research ...
... PRUSSIA, Pa., March 31 Successful and seamless completion ... to randomized patients, market research, an effective recruitment strategy, ... President and CEO Liz Moench notes: "This is achievable ... meet timelines." She adds, "We had great team chemistry ...
Other Medicine Technology:Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 2Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 3Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2
(Date:12/15/2009)... Medicare for consultations how will they get paid for patient ... understand terms. , ... Washington, DC ... will eliminate consultation codes. These codes are what healthcare ... seen for a medical consultation, whether in a provider’s office ...
(Date:12/15/2009)... Ford Health System Joins the influx of Healthcare Organizations Partnering ... ... Hazlet, N.J. (PRWEB) December 15, 2009 -- iCIMS, ... solutions , announced today that Henry Ford Health Systems has ... talent management needs. Henry Ford joins more than 30 other ...
(Date:12/15/2009)... to announce the release of a new report titled, “Incontinence ... for clinical devices used to treat and manage urinary incontinence. ... ... 15, 2009 -- Marketstrat is pleased to announce the release ... The report specifically addresses world markets for clinical devices used ...
(Date:12/15/2009)... Dec. 15, 2009 UT Southwestern Medical ... to date of the unique observable characteristics seen ... syndrome. , The findings, reported online and in ... Clinical Endocrinology and Metabolism, suggest that patients ... lumped together with those diagnosed with two similar ...
(Date:12/14/2009)... The combination of AQUALIPO™ and NaturalFill™ revolutionary new liposuction and ... wrinkling, and plump lips all in one minimally invasive treatment. ... ... -- The combination of AQUALIPO™ and NaturalFill™ can remove excess ... and lips to help people slim down, reduce facial wrinkling ...
Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 3Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 4Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 3Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3
... Two-dozen members,of the Army,s 2nd Battalion, 113th Infantry ... getting ready for their upcoming,deployment in Iraq. Instead ... a Lasik procedure that allows them to have ... ), Drs. Joseph and Jeffery Dello ...
... Airlift first by private organizations into Chengdu, STAMFORD, ... Chinese earthquake victims provided by private organizations left,Kansas City ... part of the shipment. AmeriCares is proud to play ... Province., "It will take many years for the ...
... recent study shows that pre-operative assessments of patients with ... and successful treatment of lymphedema. , The study, conducted ... National Institutes of Health (NIH) and in collaboration with ... published in the journal, Cancer (April 25, 2008). ...
... CAN HELP REVERSE MENTAL ACUITY DEFICITS IN SMOKERS ... to Address FAA,Ruling on Smoking Cessation Product, ... Federal Aviation,Administration (FAA) that it has removed a ... medications for pilots and air-traffic,controllers, it,s important to ...
... cells from embryonic stem cells, find clues to predict response ... liver cells have been generated from embryonic stem cells using ... screen for harmful side effects of new drugs before they ... reports on advances against liver diseases that were presented this ...
... Journal of Ultrasound in Medicine (JUM) includes an ... Potential Bioeffects of Diagnostic Ultrasound, which addresses issues ... is intended for use in assessing its risks ... that provide extensive evaluations of 5 bioeffects categories: ...
Other Medicine News:Health News:Soldiers Receive Free Memorial Day Lasik Surgery Before Going to Iraq 2Health News:AmeriCares Ships Medicines and Medical Supplies to Earthquake Victims in China 2Health News:New study shows positive role physical therapists play in lymphedema diagnois and treatment 2Health News:MultiVu Video Feed: FREE NICOTINE REPLACEMENT THERAPY (NRT) TO BE OFFERED TO REGISTERED PILOTS INTERESTED IN QUITTING RELIEF IN LIGHT OF RECENT FAA RULINGS 2Health News:New Hope for Liver Diseases 2Health News:New Hope for Liver Diseases 3
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
... integrates drug infusion,with patient monitoring and ... modular platform. With multiple configuration,options, you ... you,need them, keeping the number of ... while managing the unique needs of,each ...
... of infusion pumps are designed ... series of administration sets. The ... a wide variety of needleless ... featuring the patented Flo-Stop® Device ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products: